Your browser is no longer supported. Please, upgrade your browser.
Settings
CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-0.74 Insider Own0.50% Shs Outstand74.67M Perf Week1.57%
Market Cap226.29M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float56.91M Perf Month-21.82%
Income-52.50M PEG- EPS next Q-0.23 Inst Own50.70% Short Float0.71% Perf Quarter-26.91%
Sales- P/S- EPS this Y-6.80% Inst Trans9.37% Short Ratio0.43 Perf Half Y-13.71%
Book/sh0.54 P/B4.78 EPS next Y36.20% ROA-73.40% Target Price- Perf Year172.93%
Cash/sh0.60 P/C4.31 EPS next 5Y- ROE-122.10% 52W Range0.86 - 4.13 Perf YTD-19.88%
Dividend- P/FCF- EPS past 5Y35.30% ROI- 52W High-37.53% Beta0.78
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low200.00% ATR0.24
Employees22 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)37.12 Volatility6.53% 7.82%
OptionableYes Debt/Eq0.11 EPS Q/Q-42.30% Profit Margin- Rel Volume1.70 Prev Close2.51
ShortableYes LT Debt/Eq0.00 EarningsMar 17 AMC Payout- Avg Volume941.28K Price2.58
Recom2.00 SMA20-12.13% SMA50-18.54% SMA2000.44% Volume1,599,162 Change2.79%
Jun-24-20Resumed JMP Securities Mkt Outperform $3
Mar-05-19Initiated Lake Street Buy $4
Mar-26-18Initiated Needham Buy $10
Mar-07-18Initiated JMP Securities Mkt Outperform $8
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
Apr-07-21 07:00AM  
Apr-02-21 03:54PM  
Mar-31-21 11:50PM  
04:41PM  
07:00AM  
Mar-22-21 01:00PM  
10:01AM  
Mar-17-21 04:05PM  
Mar-12-21 07:00AM  
Mar-08-21 11:18PM  
Feb-24-21 06:30PM  
Feb-10-21 11:55PM  
Jan-28-21 10:58PM  
Jan-01-21 07:04AM  
Dec-08-20 07:00AM  
Dec-06-20 12:30PM  
Dec-02-20 10:24PM  
Nov-30-20 07:00AM  
Nov-10-20 04:05PM  
02:30PM  
Nov-04-20 11:41AM  
Nov-02-20 04:05PM  
Oct-26-20 11:55PM  
Oct-13-20 07:00AM  
Oct-01-20 06:52PM  
Sep-30-20 07:45AM  
Sep-29-20 04:05PM  
Aug-06-20 04:05PM  
Jul-17-20 09:54AM  
Jul-06-20 07:47PM  
Jun-22-20 03:27PM  
Jun-01-20 04:22PM  
04:00PM  
02:22PM  
07:00AM  
May-28-20 07:00AM  
May-18-20 06:25AM  
Apr-27-20 07:00AM  
Apr-08-20 07:00AM  
Mar-27-20 07:00AM  
Mar-12-20 04:05PM  
Mar-06-20 06:48PM  
Feb-21-20 04:22PM  
Feb-14-20 07:00AM  
Feb-03-20 07:01AM  
Jan-27-20 07:14AM  
Dec-16-19 05:58AM  
Dec-09-19 10:30AM  
Dec-07-19 08:35AM  
Nov-06-19 09:08AM  
Nov-04-19 04:05PM  
Oct-01-19 07:00AM  
Aug-01-19 04:05PM  
Jul-18-19 07:00AM  
Jun-13-19 07:00AM  
May-29-19 07:00AM  
May-02-19 06:40PM  
04:05PM  
Apr-03-19 07:00AM  
Mar-13-19 05:33PM  
04:05PM  
Mar-12-19 07:00AM  
Feb-25-19 05:52PM  
Feb-20-19 07:00AM  
Feb-13-19 12:22AM  
Feb-11-19 07:00AM  
Feb-08-19 06:25PM  
Feb-01-19 07:01AM  
Dec-28-18 07:00AM  
Dec-18-18 04:01PM  
Dec-17-18 07:53PM  
Dec-14-18 07:47AM  
Dec-13-18 02:20PM  
10:03AM  
Nov-26-18 04:01PM  
Nov-23-18 07:35AM  
Nov-01-18 12:10PM  
09:40AM  
08:01AM  
Oct-25-18 07:01AM  
Oct-01-18 10:05AM  
07:01AM  
Sep-26-18 07:01AM  
Sep-07-18 01:20PM  
Sep-06-18 05:50PM  
Aug-29-18 01:47PM  
Aug-02-18 02:30PM  
09:40AM  
08:36AM  
08:00AM  
Jul-26-18 04:01PM  
Jul-19-18 11:14AM  
09:14AM  
08:00AM  
Jul-18-18 11:47AM  
07:00AM  
Jul-13-18 08:50AM  
Jul-10-18 09:33AM  
Jul-09-18 05:02PM  
04:36PM  
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorApr 01Buy2.502,000,0005,000,0004,085,933Apr 05 08:15 PM
ORBIMED ADVISORS LLC10% OwnerJan 07Sale3.502,000,0007,000,0007,520,600Jan 11 04:46 PM